Analysis on the Impact of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ : IgG Fc Fusion Protein on Medical Insurance Budget
10.7664/CHE20170315
- VernacularTitle:重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对医保的预算影响分析
- Author:
Yabing ZHANG
;
Shanlian HU
;
Jiangjiang HE
- Keywords:
recombinant human tumor necrosis factor-α receptor Ⅱ : IgG Fc fusion protein;
medical insurance;
budget
- From:
Chinese Health Economics
2017;36(3):56-58
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the impact of Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ:IgG Fc Fusion Protein (rhTNFR:Fc) on medical insurance budget.Methods:Rheumatic drugs were select from the IMS data 2015.The drug quantity unit was converted to defined daily dose(DDD).The quantity of rhTNFR:FC in IMS data 2015 was taken as the baseline.The expenditure growth and its impact on rheumatic drugs and all drugs were calculated under 90％ and 80％ reimbursement rate as the different incremental proportion of the quantity of rhTNFR:Fc.National health insurance expenditure data was derived from statistical data of government departments.Results:According to 90％ reimbursement rate,medical insurance expenditure increased by 5.22～10.43 billion yuan.rheumatic drugs and all medical insurance drugs expenditure increased by 63.44～126.87％ and 0.04～0.08％ respectively while the consumption of rhTNFR:Fc increased 0-100％ in 2015.The increment of medical insurance expenditure reduced accordingly under the reimbursement ratio of 80％.Conclusion:The budget impact of rhTNFR:Fc was great on medical insurance expenditure of rheumatic drugs,which was very limited on the medical insurance expenditure of all drugs.
